SCHEMBL1626577

SCHEMBL1626577

CC1(C#N)C(=O)C(C(=O)NCC(=O)O)=C(O)c2ccc(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 13/20 0.43
VEGFA P15692 1/20 0.41
FLT1 P17948 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.38
PTGDR Q13258 1/20 0.38
SHMT1 P34896 2/20 0.36
SHMT2 P34897 2/20 0.36
EGLN3 Q9H6Z9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627969 1.00 EGLN1 (0.43) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL1626574 1.00 EGLN1 (0.43) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL1628584 0.91 EGLN1 (0.43) EGLN1VEGFAFLT1SHMT1SHMT2
SCHEMBL1626960 0.91 EGLN1 (0.43) EGLN1VEGFAFLT1SHMT1SHMT2
SCHEMBL1626276 0.91 EGLN1 (0.43) EGLN1VEGFAFLT1SHMT1SHMT2
SCHEMBL12720535 0.90 LMNA (0.40) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL12720536 0.90 LMNA (0.40) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL12752350 0.87 HPGD (0.34) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL12752349 0.87 HPGD (0.34) EGLN1VEGFAFLT1PTGDR2PTGDR
SCHEMBL12752923 0.87 HPGD (0.34) EGLN1VEGFAFLT1PTGDR2PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN EGLN1 4/4885VEGFA 445/4885FLT1 761/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN EGLN1 4/4885VEGFA 445/4885FLT1 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.